There are many recent advances in the diagnosis and management of GERD. Prolonged wireless pH monitoring has value on clinical reflux monitoring to enable the assessment of predominant exposure patterns and aid in the diagnosis of GERD.1
The most cost-effective diagnostic approach to managing patients with typical
GERD symptoms of heartburn that lack alarm symptoms and fail an empiric PPI is to offer endoscopy with ambulatory reflux monitoring followed by a trial of PPI discontinuation for patients without erosive findings.6
Bravo™ calibration-free reflux capsule
Use the Bravo™ calibration-free reflux testing system for gastroesophageal pH measurement and monitoring of gastric reflux. The capsule can be attached following either endoscopy or manometry and doesn't require pH calibration.
Bravo™ reflux recorder
The patient wears the recorder for up to 96 hours while the capsule is detecting reflux events, to record reflux data and patient activity.
Reflux software v6.1
Our reflux software supports the upload and analysis of pH and pH-impedance data collected from the Bravo™ reflux recorder and the Digitrapper™ reflux recorder. The reflux software also allows for extended recording times up to 96 hours5 via the Bravo™ calibration-free reflux testing system.
Determine therapeutic direction with two tests.
Read the instructions for cleaning products in the esophageal portfolio.
Read this quick reference guide for Bravo™ study uploading.
Advance your understanding of GERD and esophageal motility disorders including diagnostic workup and subsequent treatment considerations.
Get a high-level overview of esophageal reflux testing modalities.
See service coverage overview for GI portfolio products.
Contact a representative to download the latest reflux reader software.
1. Hirano I, Zhang Q, Pandolfino JE, et al. Four-day Bravo™ reflux testing system pH capsule monitoring with and without proton pump inhibitor therapy. Clin Gastroenterol and Hepatol. 2005;3(11):1083–1088.
2. Vaezi M, Zehrai A, and Yuksel E. Testing for refractory gastroesophageal reflux disease. American Society for Gastrointestinal Endoscopy ASGE Leading Edge. 2012;2(2):1–13.
3. Tseng D, Rizvi AZ, Fennerty MB, et al. Forty-eight hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastro Surgery. 2005;9(8):1043–1052.
4. Sweiss R, Fox M, Anggiansah R, et al. Patient acceptance and clinical impact of Bravo™ monitoring in patients with previous failed catheter-based studies. Aliment Pharmacology and Therapeutics. 2009 Mar 15;29(6):669–676.View Abstract
5. Herregods, T. V. K., et al. Patients with refractory reflux symptoms often do not have GERD: Neurogastroenterology & Motility. 2015;27(9): 1267–1273.
6. Yadlapati, R., G y awali, C. P., Pandolfino, J.E., Chang, K., Kahrilas, P. J., Katz, P. 0., Katzka, D., Komanduri, S., Lipham, J., Menard-Katcher, P., Raman Muthusamy, V., Richter, J., Sharma, V. K., Vaezi, M. F., and Wani, S. (2022). Aga clinical practice update on the personalized approach to the evaluation and management of gerd: Expert review. Clinical Gastroenterology and Hepatology. 20(5), 984–994. https://doi.org/10.1016/j.cgh.2022.01.025